The FDA approved ixekizumab (Taltz, Eli Lilly) injection 80 mg/mL for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. 
Psoriasis is an autoimmune disorder that occurs more commonly in patients with a family history of the disease, and most often begins in individuals between the ages of 15 and 35 years. Psoriasis affects approximately 7.5 million Americans, approximately 20% of whom have